Efficacy and Tolerability of a Fixed Combination of Perindopril/Amlodipine/Indapamide in Patients with Essential Hypertension: Pilot Study / Efikasnost I Tolerabilnost Fiksne Kombinacije Perindopril/Amlodipin/Indapimida Kod Pacijenata Sa Esencijalnom Hipertenzijom: Pilot Studija

Abstract Hypertension is the major risk factor in Serbia and worldwide for the morbidity and mortality from cardiovascular and cerebrovascular diseases. A majority of patients need two or more antihypertensive drugs to adequately control blood pressure. Our study group consisted of 12 patients with uncontrolled essential hypertension, without comorbidities, divided in two groups and followed for 12 weeks. The first group was treated with a single-pill of fixed-combination Perindopril 5 mg/Indapamide 1.25 mg and an additional tablet of Amlodipine 5 mg. The second group received a single-pill fixed-combination of Perindopril 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg. Our research showed significant decreases in systolic (p=0,05) and diastolic (p<0,05) blood pressure in both groups after 12 weeks of treatment. The study also showed a higher percentage of patients who achieved the targeted blood pressure (< 140/90 mmHg) on the single-pill triple combination drug (69.7%) in comparison with the other group (50%). No adverse effects were recorded in both groups. Our results revealed significant efficacy and tolerability of a single-pill triple-fixed combination Perindopril/Amlodipine/ Indapamide in patients with uncontrolled essential hypertension without comorbidities.